Cancer Treatment Reviews
Volume 37, Issue 3 , Pages 169-177 , May 2011

Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options

  • Luca Faloppi

      Affiliations

    • Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy
    • ,
  • Mario Scartozzi

      Affiliations

    • Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy
    • ,
  • Elena Maccaroni

      Affiliations

    • Scuola di Specializzazione in Oncologia, Università Politecnica delle Marche, Ancona, Italy
    • ,
  • Marzia Di Pietro Paolo

      Affiliations

    • UO Oncologia Medica, Ospedale “Profili”, Fabriano, Italy
    • ,
  • Rossana Berardi

      Affiliations

    • Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy
    • ,
  • Michela Del Prete

      Affiliations

    • Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy
    • ,
  • Stefano Cascinu

      Affiliations

    • Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy
    • Corresponding Author InformationCorresponding author. Address: Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, via Conca, 60020 Ancona, Italy. Tel.: +39 0715964169; fax: +39 0715964192.

Received 11 June 2010 ,Accepted 2 August 2010.

References 

  1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. Ca Cancer J Clin. 2005;55:74–108
  2. Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors and natural history of hepatocellular carcinoma. Ann NY Acad Sci. 2002;963:13–20
  3. Gomaa AI, Khan SA, Toledano MB, et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14(27):4300–4308
  4. La Vecchia C, Negri E, Pelucchi C. The rise and fall in primary liver cancer mortality in Italy. Digestive Liver Dis. 2002;34:169–171
  5. Bosch FX, Ribes J, Diaz M, Claries R, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–S16
  6. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37(Suppl. 2):S88–S94
  7. Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med. 2007;120:194–202
  8. Suruky RJ, Mueller N, Hayashi K, et al. Host immune status and incidence of hepatocellular carcinoma among subject infected with hepatitis C virus: a nested case-control study in Japan. Cancer Epidemiol Biomarkers Prev. 2006;15:2521–2525
  9. Liu CJ, Kao JH. Hepatitis B virus related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc. 2007;70:141–145
  10. McKillop IH, Schrum LW. Alcohol and liver cancer. Alcohol. 2005;35:195–203
  11. Voigt MD. Alcohol in hepatocellular cancer. Clin Liver Dis. 2005;9:151–169
  12. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenetic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–140
  13. Chun G, Shu-Kun Y. Diabetes mellitus: a “true” independent risk factor for hepatocellular carcinoma?. Hepatobiliary Pancreat Dis Int. 2009;8:465–473
  14. Rossi M, Lipworth L, Dal Maso L, et al. Dietary glycemic load and hepatocellular carcinoma with or without chronic hepatitis infection. Ann Oncol. 2009;20(10):1736–1740
  15. Theise ND, Park YN, Kojiro M. Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis. 2002;6:497–512
  16. Borzio M, Fargion S, Borzio F, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol. 2003;39:208–214
  17. Park YN, Chae KJ, Kim YB, Park C, Theise N. Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis. Cancer. 2001;92:2733–2738
  18. Nakashima Y, Nakashima O, Tanaka M, et al. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res. 2003;26:142–147
  19. Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis. 2003;23:385–396
  20. Sell S. Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol. 2002;13:419–424
  21. Waris G, Siddiqui A. Regulatory mechanisms of viral hepatitis B and C. J Biosci. 2003;28:311–321
  22. Tellinghuisen TL, Rice CM. Interaction between hepatitis C virus protein and host cell factors. Curr Opin Microbiol. 2002;5:419–427
  23. Block TM, Mehta AS, Fimmel CJ, et al. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22:5093–5107
  24. Giambartolomei S, Covone F, Levrero M, et al. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene. 2001;20:2606–2610
  25. Sun A, Ingelman-Sundberg M, Neve E, et al. Ethanol and oxidative stress. Alcohol Clin Exp Res. 2001;25(5 Suppl. ISBRA):237S–243S
  26. Lu SC. Regulation of glutathione synthesis. Cur Top Cell Regul. 2000;36:95–116
  27. Diehl AM. Recent events in alcoholic liver disease. V. Effects of ethanol on liver regeneration. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1–G6
  28. Llovet JM. Update treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225–235
  29. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with and-stage liver disease. Hepatology. 2001;33:464–470
  30. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442
  31. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62–67
  32. Vauthey J, Lauwers G, Esnaola N, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527–1536
  33. Greene FL. AJCC cancer staging manual. 6th ed.. New York: Springer; 2002;
  34. Okuda K, Ohtsui T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928
  35. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760–1769
  36. CLIP . Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31:840–845
  37. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol. 1999;31:133–141
  38. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396–1405
  39. Nanashima A, Sumida Y, Abo T, et al. Modified Japan integrated staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol. 2006;41:250–256
  40. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–338
  41. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797–805
  42. Bruix J, Sherman M. Management of hepatocellular carcinoma. AASLD practice guideline. Hepatology. 2005;42:1208–1236
  43. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: review of the randomized clinical trials. Lancet Oncol. 2002;3:593–603
  44. Lencioni R, Allagaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized controlled trial of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–240
  45. Lin S, Lin C, Lin C, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4cm or less. Gastroenterology. 2004;127:1714–1723
  46. Okada S. Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology. 1998;45(Suppl. 3):1259–1263
  47. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293–4300
  48. Llovet J, Ricci S, Mazzaferro V, et al. SHARP investigators. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial. J Clin Oncol. 2007;LBA1
  49. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711
  50. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109
  51. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561–574
  52. Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27:55–76
  53. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130:1117–1128
  54. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004;41:864–880
  55. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109
  56. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851–11858
  57. Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol. 2008;ù 26:4509
  58. O’Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597–3605
  59. Zhu AX, Sahani DV, di Tomaso E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2007;25:4637
  60. Faivre SJ, Raymond E, Douillard J, et al. Assessment of safety and drug induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol. 2007;25:3546
  61. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110:581–589
  62. Gruenwald V, Wilkens L, Gebel M. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol. 2007;25:A4594
  63. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23:6657–6663
  64. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110:1059–1067
  65. O’Dwyer PJ, Giantonio BJ, Levy DE, et al. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group’s Study E1203. J Clin Oncol. 2006;24:4143
  66. Ramanathan RK, Belani CP, Singh DA, et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J Clin Oncol (Meeting Abstracts). 2006;24(18S):[Abstract 4010]
  67. Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol. 2003;55–62
  68. Poon RT, Ho JW, Tong CS, et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91:1354–1360
  69. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992–2998
  70. Thomas MB, Chadha R, Iwasaki M, et al. The combination of bevacizumab and erlotinib shows significant biological activity in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2007;25:4567
  71. Schwartz J, Schwartz M, Lehrer D. Bevacizumab in unresectable hepatocellular carcinoma for patients without metastasis and without invasion of the portal vein. J Clin Oncol. 2006;24:A4144
  72. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898–1903
  73. Koch I, Baron A, Roberts S. Influence of hepatic dysfunction on safety, tolerability and pharmacokinetics of PTK787/ZK222584 in patients with unresectable HCC. J Clin Oncol. 2005;23:A4134
  74. Alberts SR, Morlan BW, Kim GP, et al. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)–interim review of toxicity. In: 2007 Gastrointestinal cancer symposium, Orlando, FL, January 19–21, 2007 [Abstract 186].
  75. Sahin F, Kannangai R, Adegbola O, et al. MTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004;10:8421–8425
  76. Ribatti D, Nico B, Mangieri D, et al. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. Histol Histopathol. 2007;22:285–289
  77. Sieghart W, Fuereder T, Schmid K, et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation. 2007;83:425–432
  78. Available at: <http://www.cancer.gov/clinicaltrials/search>.
  79. Nanashima A, Yano H, Yamaguchi H, et al. Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection. J Gastroenterol. 2004;39(2):148–154
  80. Ouchi K, Sugawara T, Ono H, et al. Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. Dig Surg. 2000;17:42–48
  81. Watanabe J, Kushihata F, Honda K, et al. Prognostic significance of Bcl-xLIto in human hepatocellular carcinoma. Surgery. 2004;135(6):604–612
  82. Fields AC, Cotsonis G, Sexton D, et al. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol. 2004;17:1378–1385
  83. Ikeguci M, Ueta T, Yamane Y, et al. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res. 2002;8(10):3131–3136
  84. O’Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol. 2000;156:393–398
  85. Kobayashi T, Kubota K, Takayama T, et al. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg. 2001;181:284–288
  86. Ohashi R, Gao C, Miyazaki M, et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 2001;21:657–662
  87. Fiorentino M, Altimari A, D’Errico A, et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res. 2000;6:3966–3972
  88. Xu X, Yamamoto H, Sakon M, et al. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin Cancer Res. 2003;9(5):1764–1772
  89. Qin LX, Tang ZY, Ma ZC, et al. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol. 2002;8(3):459–463
  90. Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res. 2001;7:594–599
  91. Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of β-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res. 2002;8:450–456
  92. Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol. 2000;32:78–84
  93. Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84:1377–1383
  94. Altimari A, Fiorentino M, Gabusi E, et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis. 2003;35:332–338
  95. Giannelli G, Bergamini C, Marinosci F, et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer. 2002;97:425–431
  96. Zheng Q, Tang ZY, Xue Q, et al. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol. 2000;126:641–646

PII: S0305-7372(10)00136-2

doi: 10.1016/j.ctrv.2010.08.001

Cancer Treatment Reviews
Volume 37, Issue 3 , Pages 169-177 , May 2011

Article Tools

* Image Usage & Resolution